|
8-Cl-cAMP Inhibits the Growth of Murine Melanoma in Vitro and in Vivo. |
|
|
Consulting or Advisory Role - Lilly/ImClone; Novartis; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical |
Research Funding - LSK Biopharma |
|
|
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD |
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical |
Speakers' Bureau - Foundation Medicine; Lilly; Merck Serono |
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical |
|
|
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha |
|
|
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Samyang |
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |